Replies to post #141942 on Biotech Values

[genisi]

Can't say I understand the mode of action of their drug though.

Prof. Cohen from the Weizmann Institute, who developed DiaPep277 believes the peptide activates a subgroup of T-cells which down-regulate the pathogenic T-cells that cause type 1 diabetes. This regulation change the cytokine profile secreted by the pathogenic T-cells: pro-inflammatory cytokines, which are lethal to the insulin-producing beta-cells, are replaced by cytokines that can inhibit inflammatory reactions and this change shuts off the immune attack on beta-cells.